BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 18179963)

  • 1. World Health Organization and international prognostic scoring system: the limitations of current classification systems in assessing prognosis and determining appropriate therapy in myelodysplastic syndromes.
    Schiffer CA
    Semin Hematol; 2008 Jan; 45(1):3-7. PubMed ID: 18179963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative review of classification systems in myelodysplastic syndromes (MDS).
    Bennett JM
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.
    Navarro I; Ruiz MA; Cabello A; Collado R; Ferrer R; Hueso J; Martinez J; Miguel A; Orero MT; Pérez P; Nolasco A; Carbonell F
    Leuk Res; 2006 Aug; 30(8):971-7. PubMed ID: 16423393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving classifications of the myelodysplastic syndromes.
    Komrokji RS; Bennett JM
    Curr Opin Hematol; 2007 Mar; 14(2):98-105. PubMed ID: 17255786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic scoring systems for risk assessment in myelodysplastic syndromes.
    Greenberg PL; Sanz GF; Sanz MA
    Forum (Genova); 1999; 9(1):17-31. PubMed ID: 10101208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The myelodysplastic syndromes: classification and prognosis.
    Komrokji R; Bennett JM
    Curr Hematol Rep; 2003 May; 2(3):179-85. PubMed ID: 12901338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical implications of the World Health Organization's classification of myelodysplastic syndromes.
    Komrokji RS; Bennett JM
    Curr Hematol Rep; 2005 May; 4(3):175-81. PubMed ID: 15865868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic indicators and scoring systems for predicting outcome in patients with myelodysplastic syndromes.
    Aul C; Giagounidis A; Heinsch M; Germing U; Ganser A
    Rev Clin Exp Hematol; 2004 Dec; 8(2):E1. PubMed ID: 16027099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes.
    Bacher U; Haferlach C; Kröger N; Schnittger S; Kern W; Wiedemann B; Zander AR; Haferlach T
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):1-11. PubMed ID: 20053328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference.
    Valent P; Horny HP; Bennett JM; Fonatsch C; Germing U; Greenberg P; Haferlach T; Haase D; Kolb HJ; Krieger O; Loken M; van de Loosdrecht A; Ogata K; Orfao A; Pfeilstöcker M; Rüter B; Sperr WR; Stauder R; Wells DA
    Leuk Res; 2007 Jun; 31(6):727-36. PubMed ID: 17257673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractory anemia and the myelodysplastic syndromes.
    Lawrence LW
    Clin Lab Sci; 2004; 17(3):178-86. PubMed ID: 15314893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Myelodysplastic syndrome].
    Urabe A
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):287-91. PubMed ID: 15791810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients.
    Bowen DT
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S16-23. PubMed ID: 16085013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Myelodysplastic syndromes].
    Paladini G; Pecorari P; De Sabbata G; Sammartini C
    Recenti Prog Med; 2004 Feb; 95(2):108-19. PubMed ID: 15072397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathobiology, classification, and diagnosis of myelodysplastic syndrome.
    Mufti GJ
    Best Pract Res Clin Haematol; 2004 Dec; 17(4):543-57. PubMed ID: 15494293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.
    Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW
    Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors and scoring systems in myelodysplastic syndromes.
    Sanz GF; Sanz MA; Greenberg PL
    Haematologica; 1998 Apr; 83(4):358-68. PubMed ID: 9592987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS).
    Fenaux P
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S11-5. PubMed ID: 16085012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
    Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelodysplastic syndromes: biology and treatment.
    Jädersten M; Hellström-Lindberg E
    J Intern Med; 2009 Mar; 265(3):307-28. PubMed ID: 19141095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.